- Home
- MSN vs KPRX Comparison
MSN vs KPRX Comparison
Compare MSN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSN
- KPRX
- Stock Information
- Founded
- MSN 1948
- KPRX 1998
- Country
- MSN United States
- KPRX United States
- Employees
- MSN N/A
- KPRX N/A
- Industry
- MSN Consumer Electronics/Appliances
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MSN Consumer Staples
- KPRX Health Care
- Exchange
- MSN Nasdaq
- KPRX Nasdaq
- Market Cap
- MSN 9.5M
- KPRX 9.2M
- IPO Year
- MSN 1994
- KPRX N/A
- Fundamental
- Price
- MSN $0.47
- KPRX $2.33
- Analyst Decision
- MSN
- KPRX Strong Buy
- Analyst Count
- MSN 0
- KPRX 1
- Target Price
- MSN N/A
- KPRX $10.00
- AVG Volume (30 Days)
- MSN 2.3M
- KPRX 51.1K
- Earning Date
- MSN 11-14-2025
- KPRX 11-07-2025
- Dividend Yield
- MSN N/A
- KPRX N/A
- EPS Growth
- MSN N/A
- KPRX N/A
- EPS
- MSN N/A
- KPRX N/A
- Revenue
- MSN $10,262,000.00
- KPRX N/A
- Revenue This Year
- MSN N/A
- KPRX N/A
- Revenue Next Year
- MSN N/A
- KPRX N/A
- P/E Ratio
- MSN N/A
- KPRX N/A
- Revenue Growth
- MSN 8.49
- KPRX N/A
- 52 Week Low
- MSN $0.28
- KPRX $2.21
- 52 Week High
- MSN $0.85
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- MSN 46.86
- KPRX 40.06
- Support Level
- MSN $0.48
- KPRX $2.22
- Resistance Level
- MSN $0.50
- KPRX $2.55
- Average True Range (ATR)
- MSN 0.07
- KPRX 0.18
- MACD
- MSN -0.01
- KPRX -0.02
- Stochastic Oscillator
- MSN 4.53
- KPRX 25.53
About MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.